Merrion Pharmaceuticals announced positive results from its Phase 2 study of Orazol (zoledronate tablet) for the treatment of hormone refractory prostate cancer patients with proven bone metastases.  This multi-center study achieved its primary endpoint by showing that weekly therapy with 20mg Orazol appears to be as therapeutically effective as monthly treatment with the intravenous drug Zometa (zoledronic acid) 4mg/vial based on movements in observed levels of critical bone biomarkers.

Orazol is a once-weekly oral tablet form of the bisphosphonate compound, zoledronic acid.

For more information call (910) 799-1847 or visit www.merrionpharma.com.